Cargando…
Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome
Down syndrome is the main cause of intellectual disabilities with a large set of comorbidities from developmental origins but also that appeared across life span. Investigation of the genetic overdosage found in Down syndrome, due to the trisomy of human chromosome 21, has pointed to one main driver...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624927/ https://www.ncbi.nlm.nih.gov/pubmed/34828439 http://dx.doi.org/10.3390/genes12111833 |
_version_ | 1784606293153021952 |
---|---|
author | Atas-Ozcan, Helin Brault, Véronique Duchon, Arnaud Herault, Yann |
author_facet | Atas-Ozcan, Helin Brault, Véronique Duchon, Arnaud Herault, Yann |
author_sort | Atas-Ozcan, Helin |
collection | PubMed |
description | Down syndrome is the main cause of intellectual disabilities with a large set of comorbidities from developmental origins but also that appeared across life span. Investigation of the genetic overdosage found in Down syndrome, due to the trisomy of human chromosome 21, has pointed to one main driver gene, the Dual-specificity tyrosine-regulated kinase 1A (Dyrk1a). Dyrk1a is a murine homolog of the drosophila minibrain gene. It has been found to be involved in many biological processes during development and in adulthood. Further analysis showed its haploinsufficiency in mental retardation disease 7 and its involvement in Alzheimer’s disease. DYRK1A plays a role in major developmental steps of brain development, controlling the proliferation of neural progenitors, the migration of neurons, their dendritogenesis and the function of the synapse. Several strategies targeting the overdosage of DYRK1A in DS with specific kinase inhibitors have showed promising evidence that DS cognitive conditions can be alleviated. Nevertheless, providing conditions for proper temporal treatment and to tackle the neurodevelopmental and the neurodegenerative aspects of DS across life span is still an open question. |
format | Online Article Text |
id | pubmed-8624927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86249272021-11-27 Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome Atas-Ozcan, Helin Brault, Véronique Duchon, Arnaud Herault, Yann Genes (Basel) Review Down syndrome is the main cause of intellectual disabilities with a large set of comorbidities from developmental origins but also that appeared across life span. Investigation of the genetic overdosage found in Down syndrome, due to the trisomy of human chromosome 21, has pointed to one main driver gene, the Dual-specificity tyrosine-regulated kinase 1A (Dyrk1a). Dyrk1a is a murine homolog of the drosophila minibrain gene. It has been found to be involved in many biological processes during development and in adulthood. Further analysis showed its haploinsufficiency in mental retardation disease 7 and its involvement in Alzheimer’s disease. DYRK1A plays a role in major developmental steps of brain development, controlling the proliferation of neural progenitors, the migration of neurons, their dendritogenesis and the function of the synapse. Several strategies targeting the overdosage of DYRK1A in DS with specific kinase inhibitors have showed promising evidence that DS cognitive conditions can be alleviated. Nevertheless, providing conditions for proper temporal treatment and to tackle the neurodevelopmental and the neurodegenerative aspects of DS across life span is still an open question. MDPI 2021-11-20 /pmc/articles/PMC8624927/ /pubmed/34828439 http://dx.doi.org/10.3390/genes12111833 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Atas-Ozcan, Helin Brault, Véronique Duchon, Arnaud Herault, Yann Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome |
title | Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome |
title_full | Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome |
title_fullStr | Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome |
title_full_unstemmed | Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome |
title_short | Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome |
title_sort | dyrk1a from gene function in development and physiology to dosage correction across life span in down syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624927/ https://www.ncbi.nlm.nih.gov/pubmed/34828439 http://dx.doi.org/10.3390/genes12111833 |
work_keys_str_mv | AT atasozcanhelin dyrk1afromgenefunctionindevelopmentandphysiologytodosagecorrectionacrosslifespanindownsyndrome AT braultveronique dyrk1afromgenefunctionindevelopmentandphysiologytodosagecorrectionacrosslifespanindownsyndrome AT duchonarnaud dyrk1afromgenefunctionindevelopmentandphysiologytodosagecorrectionacrosslifespanindownsyndrome AT heraultyann dyrk1afromgenefunctionindevelopmentandphysiologytodosagecorrectionacrosslifespanindownsyndrome |